Applies to oxytocin: parenteral injection
Side effects include:
Adverse effects usually are dose related.
Uterine hyperstimulation and subsequent fetal heart rate deceleration most common. (See Uterine Hyperactivity under General Precautions.)
Maternal nausea, vomiting, sinus bradycardia, premature ventricular complexes; probably related to labor and not the drug.
Neonatal hyperbilirubinemia, jaundice, retinal hemorrhage, low Apgar scores at 5 minutes.
Applies to oxytocin: compounding powder, injectable solution, intravenous solution
The more commonly reported adverse effects have included headache, tachycardia, bradycardia, nausea and vomiting.
Common (1% to 10%): Tachycardia, bradycardia
Frequency not reported: Premature ventricular contractions, hypertensive episodes, cardiac arrhythmia, bradycardia (neonate), premature ventricular contractions and other arrhythmias (neonate)
Postmarketing reports: Myocardial ischemia, QTc prolongation, hypotension, flushing
Bradycardia and premature ventricular contractions and other arrhythmias have been reported in the neonate due to induced uterine motility.
Permanent CNS or brain damage, and seizures have been reported in the neonate due to induced uterine motility.
Common (1% to 10%): Headache
Frequency not reported: Subarachnoid hemorrhage, permanent CNS or brain damage (neonate), neonatal seizures
Frequency not reported: Severe water intoxication with convulsions, coma, fatal water intoxication
Postmarketing reports: Maternal hyponatremia, neonatal hyponatremia
Frequency not reported: Anaphylactic reaction
Postmarketing reports: Anaphylactic reaction and shock
Frequency not reported: Uterine Rupture, pelvic hematoma, postpartum hemorrhage
Postmarketing reports: Uterine hypertonicity, tetanic contractions, rupture of the uterus; fetal distress (neonate), amniotic fluid embolism
Frequency not reported: Fatal afibrinogenemia
Postmarketing reports: Disseminated intravascular coagulation
Frequency not reported: Neonatal jaundice
Neonatal jaundice has been reported in the neonate due to use of oxytocin in the mother.
Common (1% to 10%): Nausea, vomiting
Postmarketing reports: Acute pulmonary edema, asphyxia (neonate)
Neonatal retinal hemorrhage has been reported in the neonate due to use of oxytocin in the mother.
Frequency not reported: Neonatal retinal hemorrhage
Fetal death has been reported due to induced uterine motility; low Apgar scores at 5 minutes have been reported in the neonate due to oxytocin use in the mother.
Frequency not reported: Fetal death, low Apgar scores at 5 minutes
Postmarketing reports: Angioedema
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Oxytocin